First Wave BioPharma Inc reports results for the quarter ended in December - Earnings Summary

GridAI Technologies

01/04/2024 22:01

* First Wave BioPharma Inc  FWBI.OQ  reported a quarterly
adjusted
loss of $5.35​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-189.40.  The mean expectation of two analysts
for the quarter was for a loss of $4.03 per share. Wall Street
expected results to range from $-4.93 to $-3.14 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * First Wave BioPharma Inc's reported EPS for the quarter
was a
loss of $5.35​.
    * The company reported a quarterly loss of $4.18 million.
    * First Wave BioPharma Inc shares had held steady so far
this
quarter and gained 4.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for First Wave
BioPharma Inc is $36.00 
This summary was machine generated from LSEG data April 1 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -4.03          -5.35          Missed
 Sep. 30 2023      -12.30         -9.20          Beat
 Jun. 30 2023      -20.80         -37.80         Missed
 Mar. 31 2023      -42.60         -36.40         Beat